NO306398B1 - Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat - Google Patents

Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat

Info

Publication number
NO306398B1
NO306398B1 NO961664A NO961664A NO306398B1 NO 306398 B1 NO306398 B1 NO 306398B1 NO 961664 A NO961664 A NO 961664A NO 961664 A NO961664 A NO 961664A NO 306398 B1 NO306398 B1 NO 306398B1
Authority
NO
Norway
Prior art keywords
glycinamides
indole
carbonyl
substituted
pharmaceutical composition
Prior art date
Application number
NO961664A
Other languages
English (en)
Other versions
NO961664L (no
NO961664D0 (no
Inventor
Bernard Hulin
Judith Lee Treadway
William Holt Martin
Dennis Jay Hoover
Douglas Phillips
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO961664D0 publication Critical patent/NO961664D0/no
Publication of NO961664L publication Critical patent/NO961664L/no
Publication of NO306398B1 publication Critical patent/NO306398B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO961664A 1995-06-06 1996-04-25 Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat NO306398B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000442 WO1996039384A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

Publications (3)

Publication Number Publication Date
NO961664D0 NO961664D0 (no) 1996-04-25
NO961664L NO961664L (no) 1996-12-09
NO306398B1 true NO306398B1 (no) 1999-11-01

Family

ID=11004338

Family Applications (2)

Application Number Title Priority Date Filing Date
NO961664A NO306398B1 (no) 1995-06-06 1996-04-25 Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat
NO990405A NO990405D0 (no) 1995-06-06 1999-01-28 Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO990405A NO990405D0 (no) 1995-06-06 1999-01-28 Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler

Country Status (37)

Country Link
US (1) US6107329A (no)
EP (1) EP0832065B1 (no)
JP (1) JP3314938B2 (no)
KR (1) KR100191992B1 (no)
CN (2) CN1142492A (no)
AP (1) AP623A (no)
AR (1) AR003955A1 (no)
AT (1) ATE206702T1 (no)
AU (1) AU701465B2 (no)
BG (1) BG100547A (no)
BR (1) BR9602542A (no)
CA (2) CA2342471C (no)
CO (1) CO4700440A1 (no)
CZ (1) CZ157396A3 (no)
DE (1) DE69523182T2 (no)
DK (1) DK0832065T3 (no)
FI (1) FI974436A (no)
HR (1) HRP960244A2 (no)
HU (1) HUP9601475A2 (no)
IL (1) IL118029A0 (no)
IS (1) IS4341A (no)
LV (1) LV11613B (no)
MA (1) MA23866A1 (no)
MX (1) MX9709875A (no)
NO (2) NO306398B1 (no)
NZ (1) NZ286460A (no)
OA (1) OA10581A (no)
PL (1) PL314561A1 (no)
RU (1) RU2143424C1 (no)
SG (1) SG44947A1 (no)
SI (1) SI9600177A (no)
SK (1) SK69996A3 (no)
TN (1) TNSN96072A1 (no)
TR (1) TR199600456A2 (no)
TW (1) TW346485B (no)
WO (1) WO1996039384A1 (no)
YU (1) YU34896A (no)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0832065T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)glycinamider og derivater som glycogenphosphorylaseinhibitorer
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
SK141899A3 (en) 1997-04-15 2000-09-12 Csir Corporate Building Pharmaceutical compositions having appetite suppressant activity
UA57811C2 (uk) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (en) * 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
WO2000042213A1 (en) 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6316489B1 (en) 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) * 1999-06-18 2002-06-25 Pfizer Inc. Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US20060160740A1 (en) * 1999-10-21 2006-07-20 Suad Efendic Use of GLP-1 or analogs in treatment of stroke
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
YU32702A (sh) 1999-11-04 2005-06-10 Ortho-Mcneil Pharmaceutical Inc. Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina
US20030139434A1 (en) 2000-01-21 2003-07-24 Bork Balkan Combinations comprising dipeptidylpeptidase-iv inhibitor
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AR027656A1 (es) * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
WO2001085693A1 (fr) * 2000-05-11 2001-11-15 Banyu Pharmaceutical Co., Ltd. Dérivés n-acyltétrahydroisoquinoline
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ATE308537T1 (de) 2001-05-10 2005-11-15 Solvay Pharm Gmbh Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
CA2464214C (en) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
JPWO2003037864A1 (ja) * 2001-10-29 2005-02-17 日本たばこ産業株式会社 インドール化合物及びその医薬用途
FR2834214B1 (fr) * 2001-12-28 2004-09-24 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
CA2472205A1 (en) * 2002-01-18 2003-07-24 Frank Robert Busch Intermediates for preparing glycogen phosphorylase inhibitors
MXPA03000966A (es) * 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
WO2003091213A1 (fr) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
CA2503727A1 (en) 2002-11-07 2004-05-21 Pfizer Products Inc. Anti-diabetic agents
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
JP2006519229A (ja) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
WO2004094394A1 (en) * 2003-04-01 2004-11-04 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
MXPA05011176A (es) * 2003-04-17 2005-12-14 Pfizer Prod Inc Derivados de carboxamida como agentes antidiabeticos.
MXPA05011702A (es) * 2003-04-30 2006-01-23 Pfizer Prod Inc Agentes antidiabeticos.
US7385055B2 (en) * 2003-05-19 2008-06-10 Board Of Trustees Of Michigan State University Preparation of hymenialdisine derivatives and use thereof
BRPI0410445B1 (pt) * 2003-05-21 2017-11-28 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitor compound of glycogen phosphorylase, pharmaceutical composition comprising the same, process for its production and intermediate compounds
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
CA2527806A1 (en) * 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
SI1689757T1 (sl) 2003-11-12 2015-01-30 Sino-Med International Alliance, Inc. Heterociklične spojine boronske kisline
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1725555B1 (en) 2004-03-08 2010-10-06 Prosidion Ltd. Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US7786163B2 (en) 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
US20090099176A1 (en) 2004-12-02 2009-04-16 Thomas Martin Krulle Pyrrolopyridine-2-carboxylic acid amides
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
US8691835B2 (en) 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
BRPI0609464A2 (pt) * 2005-05-23 2010-04-13 Japan Tobacco Inc composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
DK1931350T4 (en) 2005-09-14 2021-09-20 Takeda Pharmaceuticals Co Administration af inhibitorer af dipeptidylpeptidase
CN100519524C (zh) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
JP5249226B2 (ja) * 2006-09-13 2013-07-31 サノフイ 凝固第ＩＸａ因子インヒビターとしての使用のためのイソセリン誘導体
WO2008062739A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles et leur utilisation en tant que médicaments
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
AU2007333737A1 (en) * 2006-12-18 2008-06-26 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
CN101279955B (zh) * 2007-04-03 2012-11-28 北京摩力克科技有限公司 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
CN102076680B (zh) 2008-04-28 2016-03-02 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的苯并咪唑
EA201100189A1 (ru) 2008-07-15 2011-08-30 Новартис Аг Гетероарильные производные в качестве ингибиторов dgat1
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PT2531501E (pt) 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
CN102453001B (zh) * 2010-10-22 2016-06-01 中国医学科学院药物研究所 硫代吗啉类化合物及其制备方法和用途
US9409880B2 (en) * 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
JP2014513923A (ja) 2011-03-04 2014-06-19 ファイザー・インク Ｅｄｎ３様ペプチドおよびその使用
CN103582630B (zh) * 2011-05-31 2016-08-17 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
JP6122862B2 (ja) 2011-10-25 2017-04-26 ヤンセン ファーマシューティカ エヌ．ベー． １−（５，６−ジクロロ−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−１ｈ−ピラゾール−４−カルボン酸のメグルミン塩製剤
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN103497181B (zh) 2013-09-30 2016-03-30 承德医学院 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途
JP2017506666A (ja) * 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108329330B (zh) * 2017-01-20 2021-05-04 复旦大学 2-苄氧苯基噁唑并吡啶类化合物及其药物用途
CN108191845A (zh) * 2018-02-12 2018-06-22 李化绪 一种异恶唑亚氨基类化合物及其在降血脂药物中的应用
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764610A (en) * 1981-07-16 1988-08-16 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
US4836846A (en) * 1981-07-16 1989-06-06 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
NZ202232A (en) * 1981-11-06 1985-08-16 Smithkline Beckman Corp N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
US4933325A (en) * 1985-08-14 1990-06-12 G. D. Searle & Co. Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4757151A (en) * 1985-11-14 1988-07-12 Warner-Lambert Company 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl]
US4902708A (en) * 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US5089638A (en) * 1986-06-16 1992-02-18 Merck & Co., Inc. Amino acid analogs as CCK-antagonists
MY103189A (en) * 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
WO1988003022A1 (en) * 1986-10-31 1988-05-05 Pfizer Inc. Relatively low molecular weight polypeptides as renin inhibitors
US5034376A (en) * 1986-10-31 1991-07-23 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
IL85728A (en) * 1987-03-25 1993-01-14 Bio Mega Inc Fluorine containing atrial natriuretic peptides, their preparation and pharmaceutical compositions containing them
EP0288965A2 (de) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptide mit Phospholipase A2- hemmender Wirkung
US5128346A (en) * 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en) * 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
EP0336356A3 (en) * 1988-04-05 1991-09-25 Abbott Laboratories Derivatives of tryptophan as cck antagonists
US4904846A (en) * 1988-04-29 1990-02-27 Augustin Oscadal Oil filled body heater
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
US5010089A (en) * 1988-08-12 1991-04-23 Biomeasure, Inc. CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (fr) * 1989-02-17 1993-11-05 Roussel Uclaf Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) * 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
DK0431520T3 (da) * 1989-12-04 1995-04-10 Searle & Co Heterocycliske acylaminodiol-beta-aminosyrederivater
KR927003625A (ko) * 1990-02-09 1992-12-18 미셀 모르뱅 N-페닐-n-아세트아미도 글리신아미드, 제조방법 및 이들을 함유하는 약물
JPH05504968A (ja) * 1990-03-07 1993-07-29 ローン―プーラン・ロレ・ソシエテ・アノニム グリシンアミド誘導体、その製造及びそれを含む医薬品
JPH03294253A (ja) * 1990-04-12 1991-12-25 Shionogi & Co Ltd 消化管ホルモン拮抗物質
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994006755A1 (en) * 1992-09-18 1994-03-31 Japan Tobacco Inc. Alcohol derivative having renin-inhibiting activity and use thereof
WO1994007815A2 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
WO1995034538A2 (en) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof
DK0832065T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)glycinamider og derivater som glycogenphosphorylaseinhibitorer

Also Published As

Publication number Publication date
BG100547A (bg) 1996-12-31
ATE206702T1 (de) 2001-10-15
NO961664L (no) 1996-12-09
LV11613B (en) 1997-04-20
CZ157396A3 (en) 1997-03-12
SK69996A3 (en) 1997-08-06
CO4700440A1 (es) 1998-12-29
CN1140709A (zh) 1997-01-22
SG44947A1 (en) 1997-12-19
AR003955A1 (es) 1998-09-30
OA10581A (en) 2002-08-28
HU9601475D0 (en) 1996-07-29
CA2342471C (en) 2002-10-29
FI974436A0 (fi) 1997-12-05
CA2224062C (en) 2001-09-04
LV11613A (lv) 1996-12-20
TW346485B (en) 1998-12-01
KR100191992B1 (ko) 1999-06-15
DK0832065T3 (da) 2001-11-19
NZ286460A (en) 1998-09-24
MX9709875A (es) 1998-03-31
AP623A (en) 1997-12-19
BR9602542A (pt) 1998-10-27
TNSN96072A1 (fr) 2005-03-15
CA2224062A1 (en) 1996-12-12
NO990405L (no) 1999-01-28
IL118029A0 (en) 1996-08-04
WO1996039384A1 (en) 1996-12-12
HUP9601475A2 (hu) 1998-09-28
RU2143424C1 (ru) 1999-12-27
JP3314938B2 (ja) 2002-08-19
US6107329A (en) 2000-08-22
AU701465B2 (en) 1999-01-28
HRP960244A2 (en) 1997-12-31
CN1098838C (zh) 2003-01-15
MA23866A1 (fr) 1996-12-31
CA2342471A1 (en) 1996-12-12
AP9600803A0 (en) 1996-04-30
PL314561A1 (en) 1996-12-09
KR970001322A (ko) 1997-01-24
DE69523182D1 (en) 2001-11-15
SI9600177A (en) 1997-02-28
YU34896A (sh) 1999-09-27
CN1142492A (zh) 1997-02-12
JPH10511687A (ja) 1998-11-10
FI974436A (fi) 1998-01-27
NO961664D0 (no) 1996-04-25
AU5462696A (en) 1996-12-19
IS4341A (is) 1996-12-07
EP0832065A1 (en) 1998-04-01
DE69523182T2 (de) 2002-02-07
EP0832065B1 (en) 2001-10-10
TR199600456A2 (tr) 1996-12-21
NO990405D0 (no) 1999-01-28

Similar Documents

Publication Publication Date Title
NO306398B1 (no) Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat
IS1846B (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO308533B1 (no) Heteroarylaminer, anvendelse derav og farmasøytisk preparat
NO306401B1 (no) Oksazolidindionderivater, farmasöytisk preparat inneholdende slike derivater, og deres anvendelse
DK0720609T3 (da) 3-(5-Tetrazolylbenzyl)aminoperidinderivater og antagonister for tachykininer
NO306257B1 (no) 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
DK0804078T3 (da) Sammensætning og anvendelse deraf
DE69300913D1 (de) Polymorph Terazosin und pharmazeutische Zusammenstellung.
NO20004274L (no) Proteaseaktivert reseptor 4 og anvendelse derav
NO308896B1 (no) Benzazepinderivat, farmasøytisk preparat inneholdende dette, og mellomprodukter for dette
NO20004277D0 (no) Indolderivater og farmasøytiske sammensetninger omfattende det samme
DK0755386T3 (da) Benzamid-derivater, sammensætninger indeholdende nævnte derivat og anvendelse deraf
NO973980D0 (no) Imiadazolderivater og medisinsk preparat
NO940130D0 (no) Benzimidazolderivater, fremgangsmaate for deres fremstilling og te rapeutisk anvendelse derav
NO973230D0 (no) Nye peptider, deres fremstilling og anvendelse
NO971188L (no) Nye PKA-bindingsproteiner og anvendelse derav
NO307512B1 (no) Nye indolforbindelser, farmasøytisk preparat inneholdende slike forbindelser, og deres anvendelse
NO983492D0 (no) 2,3-disubstituerte cyklopentanderivater, fremgangsmÕte for fremstilling derav, og medisinsk anvendelse derav
NO307826B1 (no) Terapeutiske amider og farmasøytisk preparat
NO943236D0 (no) Nye 1,2-ditiol-3-tionderivater og farmasöytisk preparat inneholdende disse
NO306613B1 (no) Oligomer og farmasöytisk preparat omfattende denne
NO960796L (no) Benzotiofenonforbindelser, mellomprodukter, sammensetninger og fremgangsmåter